Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...
BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares. With sufficient cash to support “years of development in ...
Current exhibit features work of artists from Vancouver Island and the Gulf Islands until Feb. 19.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback